Analytical Data
-
Gene name
MCL1
- Application
-
Alternative Names
MCL1;BCL2L3;Induced myeloid leukemia cell differentiation Protein Mcl-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q07820
-
Expression Region
1-327aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MFGLKRNAVI GLNLYCGGAG LGAGSGGATR PGGRLLATEK EASARREIGG GEAGAVIGGS AGASPPSTLT PDSRRVARPP PIGAEVPDVT ATPARLLFFA PTRRAAPLEE MEAPAADAIM SPEEELDGYE PEPLGKRPAV LPLLELVGES GNNTSTDGSL PSTPPPAEEE EDELYRQSLE IISRYLREQA TGAKDTKPMG RSGATSRKAL ETLRRVGDGV QRNHETAFQG MLRKLDIKNE DDVKSLSRVM IHVFSDGVTN WGRIVTLISF GAFVAKHLKT INQESCIEPL AESITDVLVR TKRDWLVKQR GWDGFVEFFH VEDLEGG
-
Molecular Weight
37 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MCL-1 (Myeloid Cell Leukemia 1) is a member of the B-cell lymphoma-2 (Bcl-2) family of proteins, which are critical regulators of the apoptotic pathway, influencing cell survival and death. Its dysregulation has been associated with various cancers, particularly hematological malignancies and solid tumors, making it a compelling target for cancer therapy. The MCL-1 protein functions primarily as an anti-apoptotic factor, and its overexpression is linked to resistance to chemotherapy and poor patient prognosis. Research into MCL-1 has gained momentum due to its unique structure and function, distinguishing it from other Bcl-2 family members. The development of MCL-1 inhibitors is a promising therapeutic avenue, aiming to restore the apoptotic process in cancer cells. Furthermore, studies have begun focusing on the mechanisms governing MCL-1 stability and degradation, as these processes play a crucial role in its oncogenic potential. By producing recombinant MCL-1 protein, researchers can study its interactions, better understand its function, and assess the efficacy of potential inhibitors. This area of research not only provides insights into the fundamental biological processes of cell death but also holds the potential for significant advancements in the treatment of malignancies characterized by MCL-1 overexpression. The ongoing exploration of MCL-1’s role in cancer biology, combined with innovative therapeutic strategies targeting its activity, underscores the importance of this protein in improving cancer treatment outcomes and developing personalized therapies.
